Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Eli Lilly just reported pivotal Phase 3 results for retatrutide and the numbers are unprecedented in pharmacological obesity treatment: The Headline Numbers: 28.3% weight loss at 80 weeks (12 mg dose) 70.3 lbs average 45.3% of patients achieved 30% weight loss a threshold previously associated almost exclusively with bariatric surgery 65% of patients on 12 mg achieved non-obese BMI (BMI 18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure
Dramatic responses have been reported including regression of involved lymph nodes
To see important safety information regarding the use of compounded tirzepatide, click here
Men in Europe interested in PT-141 might have to wait for future approvals or research trials, or obtain it through special channels that allow importation of non-approved medicines (if permitted)
A C20 fatty diacid moiety facilitates albumin binding, protecting the peptide from enzymatic degradation and extending its half-life to approximately 6 days in research models a structural feature that distinguishes it from shorter-acting GLP-1 analogs and supports weekly administration protocols in preclinical study designs
US$ 28.17
US$ 20.53
US$ 20.57
US$ 25.70
US$ 27.23
US$ 23.56
US$ 20.10
US$ 22.49
